Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Jacobson PharmaHKSE:02633 -0.96%56 Return-on-Tangible-Equity is 17.27% as of Mar. 2026, which is 8% above its 10-year median of 15.92. GuruFocus rates HKSE:02633 with a GF Score™ of 56/100 and a GF Value™ of HK$0.85 (Modestly Overvalued). The stock has 2 warning signs investors should review. Among 895 Drug Manufacturers companies, Jacobson Pharma ranks better than 71.4% on this metric.
Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Jacobson Pharma's annualized net income for the quarter that ended in Mar. 2026 was HK$319 Mil. Jacobson Pharma's average shareholder tangible equity for the quarter that ended in Mar. 2026 was HK$1,848 Mil. Therefore, Jacobson Pharma's annualized Return-on-Tangible-Equity for the quarter that ended in Mar. 2026 was 17.27%.
The historical rank and industry rank for Jacobson Pharma's Return-on-Tangible-Equity or its related term are showing as below:
HKSE:02633'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: 15.16 Med: 15.92 Max: 30.58
Current: 15.8
During the past 13 years, Jacobson Pharma's highest Return-on-Tangible-Equity was 30.58%. The lowest was 15.16%. And the median was 15.92%.
HKSE:02633's Return-on-Tangible-Equity is ranked better than 71.4% of 895
companies
in the Drug Manufacturers industry
Industry Median: 7.5
vs HKSE:02633: 15.80
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
Jacobson Pharma Return-on-Tangible-Equity Related Terms
Jacobson Pharma Return-on-Tangible-Equity Historical Data
* Premium members only.
The historical data trend for Jacobson Pharma's Return-on-Tangible-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HKSE:02633 vs ZTS: Return-on-Tangible-Equity Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Jacobson Pharma's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Jacobson Pharma Return-on-Tangible-Equity vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Jacobson Pharma's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where Jacobson Pharma's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is two times the semi-annual (Mar. 2026) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of 17.27% mean?
Jacobson Pharma (HKSE:02633) has a Return-on-Tangible-Equity of 17.27% as of Mar. 2026. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Jacobson Pharma and its competitors. This is near median its historical median of 15.92. Over the past decade, Jacobson Pharma's Return-on-Tangible-Equity has ranged from 15.16 to 30.58. According to the industry distribution chart, Jacobson Pharma ranks #256 out of 895 companies in the Drug Manufacturers industry, placing it in the top 28.6%.
Is Jacobson Pharma's Return-on-Tangible-Equity too high?
Jacobson Pharma's current Return-on-Tangible-Equity of 17.27% is near median its 10-year median of 15.92. Over the past 10 years, this metric has ranged from a low of 15.16 to a high of 30.58. The Drug Manufacturers industry median Return-on-Tangible-Equity is 7.50. Jacobson Pharma's value of 17.27% is 130.3% above this industry median. Based on the distribution chart, Jacobson Pharma ranks #256 out of 895 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Jacobson Pharma has a GF Score™ of 56/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Jacobson Pharma's Return-on-Tangible-Equity compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Jacobson Pharma ranks #256 out of 895 companies for Return-on-Tangible-Equity. This puts Jacobson Pharma in the upper half of its industry. The industry median Return-on-Tangible-Equity is 7.50. Jacobson Pharma's value of 17.27% is 130.3% above this benchmark. Historically, Jacobson Pharma's own Return-on-Tangible-Equity has ranged from 15.16 to 30.58 over the past decade. While the company's 10-year median is 15.92 vs. the industry median of 7.50, Jacobson Pharma has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Drug Manufacturers company?
The median Return-on-Tangible-Equity among Drug Manufacturers companies is 7.50, based on 895 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Equity significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Jacobson Pharma's current Return-on-Tangible-Equity of 17.27% is 130.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Jacobson Pharma and its competitors. For the Drug Manufacturers industry, the median Return-on-Tangible-Equity is 7.50 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Jacobson Pharma's current Return-on-Tangible-Equity is 17.27%, which is near median its own 10-year median of 15.92. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Jacobson Pharma stock overvalued right now?
Based on GuruFocus' analysis, Jacobson Pharma (HKSE:02633) is currently considered Modestly Overvalued. The stock's GF Value™ is HK$0.85, compared to a current price of HK$1.04 — trading 21.8% above its estimated fair value. The current Return-on-Tangible-Equity is 17.27%, which is near median its 10-year median of 15.92 and 130.3% above the Drug Manufacturers industry median of 7.50. Jacobson Pharma's overall GF Score™ is 56/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For Jacobson Pharma (HKSE:02633), the current Return-on-Tangible-Equity is 17.27% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Jacobson Pharma (HKSE:02633) Overvalued in 2026?
Based on GuruFocus' analysis, Jacobson Pharma stock appears to be overvalued.
The current stock price of HK$1.04 is trading 21.8% above its estimated GF Value™ of HK$0.85.
GuruFocus considers Jacobson Pharma to be Modestly Overvalued.
Key valuation signals for HKSE:02633:
Return-on-Tangible-Equity: 17.27% (near median its 10-year median of 15.92)
GF Value™: HK$0.85 vs. price of HK$1.04 (21.8% above fair value)
Industry Position: 130.3% above the Drug Manufacturers median (#256 of 895)
No single metric tells the full story. See the HKSE:02633 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Jacobson Pharma Corp Ltd is an investment holding company. It is principally engaged in the development, production, marketing, and sale of generic drugs. The company's operating segment includes Generic drugs; Branded healthcare, Wholesale, and retail The generic drugs segment develops, manufactures, and distributes a host of off-patent medicines for various therapeutic use. It generates maximum revenue from the Generic drugs segment. Geographically, it derives a majority of its revenue from Hong Kong and also has a presence in Mainland China, Macau, Singapore, and Other Countries.
56GF Score
Get the complete analysis for HKSE:02633
Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:02633 has been successfully added to your 
